The new insulins

Pediatric Emergency Care

Volumn 23, Issue 12, 2007, Pages 903-908

  Crotty, Stephen ^a,b   Reynolds, Sally L ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Hypoglycemia; Inhaled insulin; Insulin; Insulin analogues

Indexed keywords

AERX INSULIN; DETEMIR; GLULISINE; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COUGHING; DIABETES CONTROL; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DYSPNEA; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; PHARMACODYNAMICS; REVIEW; SORE THROAT; XEROSTOMIA;

ADMINISTRATION, INHALATION; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 37349112668     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/pec.0b013e31816121ba     Document Type: Review

References (17)

1. Center for Disease Control Fact Sheet 2005. Available at: www.cdc.gov/diabetes.
2. Levinson P. Eighty Years of Insulin Therapy: 1922-2002. Rhode Island: Med and Health; 2003.
3. Hirsch I. Insulin analogues. N Engl J Med. 2005;352:174-183.
4. Patton JS, Bakar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev. 1999;35:235-247.
5. Mandal TK. Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm. 2005;62:1359-1364.
6. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized controlled trial. Ann Intern Med. 2005;143:549-558.
7. Gerber RA, Cappelleri JC, Kourides IA, et al. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2001;24:1556-1559.
8. Quattrin T, Belanger A, Bohannon NJ, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2622-2627.
9. FDA Home Page. www.fda.gov. Available at: hhtp://www. drugdevelopmenttechnology.com/projects/exubera. Accessed March 2007.
10. Owens DR, Zinamn B. Alternative routes of insulin delivery. Diabet Med. 2003;20:886-898.
11. Henry RR, Mudaliar SRD, Howland WC III, et al. Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care. 2003;26:764-769.
12. Vazquez-Carrera M. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol. 2004;26:445-461.
13. Girish C, Manikandan S, Jayanthi M. Newer insulin analogues and inhaled insulins. Indian J Med Sci. 2006;60:117-123.
14. Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356:443-445.
15. Heise T, Nosek L, Ronn BB, et al. Lower within subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
16. Hermansen K. Comparison of the soluble basal insulin analogue insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care. 2001;24:296-301.
17. Vague P, Selam J. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26:590-596.